Stock Track | CMS Soars 5.09% Intraday After Analyst Upgrade and Target Price Hike

Stock Track03-18

CMS's stock price surged 5.09% during intraday trading on Wednesday, following a bullish research report from a major brokerage.

The sharp rise came after CICC maintained its Outperform rating on CMS and raised its target price by 6% to HK$17.50, implying a potential upside of 35% from current levels. The brokerage also increased its adjusted net profit forecasts for the company for 2026 and 2027, citing contributions from new product sales and an effective strategic transformation.

Key drivers highlighted in the report include the company's 2025 results meeting expectations, with innovative drugs and exclusive products becoming the core growth engine. The skin health business saw remarkable growth of 73.2% year-on-year, supported by plans to spin off Demai Pharmaceutical for a separate listing and the recent approval of a core vitiligo product. A robust product pipeline and significant R&D investments further underpin the positive outlook.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1144733107?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 13:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144733107","market":"hk","top_or_hot":-1,"title":"Stock Track | CMS Soars 5.09% Intraday After Analyst Upgrade and Target Price Hike","media":"Stock Track","content":"<p>CMS's stock price surged 5.09% during intraday trading on Wednesday, following a bullish research report from a major brokerage.</p><p>The sharp rise came after CICC maintained its Outperform rating on CMS and raised its target price by 6% to HK$17.50, implying a potential upside of 35% from current levels. The brokerage also increased its adjusted net profit forecasts for the company for 2026 and 2027, citing contributions from new product sales and an effective strategic transformation.</p><p>Key drivers highlighted in the report include the company's 2025 results meeting expectations, with innovative drugs and exclusive products becoming the core growth engine. The skin health business saw remarkable growth of 73.2% year-on-year, supported by plans to spin off Demai Pharmaceutical for a separate listing and the recent approval of a core vitiligo product. A robust product pipeline and significant R&D investments further underpin the positive outlook.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CMS Soars 5.09% Intraday After Analyst Upgrade and Target Price Hike</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CMS Soars 5.09% Intraday After Analyst Upgrade and Target Price Hike\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-18 13:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CMS's stock price surged 5.09% during intraday trading on Wednesday, following a bullish research report from a major brokerage.</p><p>The sharp rise came after CICC maintained its Outperform rating on CMS and raised its target price by 6% to HK$17.50, implying a potential upside of 35% from current levels. The brokerage also increased its adjusted net profit forecasts for the company for 2026 and 2027, citing contributions from new product sales and an effective strategic transformation.</p><p>Key drivers highlighted in the report include the company's 2025 results meeting expectations, with innovative drugs and exclusive products becoming the core growth engine. The skin health business saw remarkable growth of 73.2% year-on-year, supported by plans to spin off Demai Pharmaceutical for a separate listing and the recent approval of a core vitiligo product. A robust product pipeline and significant R&D investments further underpin the positive outlook.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00867","symbol_name":"康哲药业","start_time":0,"source_url":"","article_id":"1144733107","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144733107","pubTimestamp":1773812717,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CMS's stock price surged 5.09% during intraday trading on Wednesday, following a bullish research report from a major brokerage.The sharp rise came after CICC maintained its Outperform rating on CMS...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00867":"康哲药业"},"translate_title":"个股轨迹|分析师上调评级及目标价上调后康哲药业盘中大涨5.09%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00867":1},"content_text":"CMS's stock price surged 5.09% during intraday trading on Wednesday, following a bullish research report from a major brokerage.The sharp rise came after CICC maintained its Outperform rating on CMS and raised its target price by 6% to HK$17.50, implying a potential upside of 35% from current levels. The brokerage also increased its adjusted net profit forecasts for the company for 2026 and 2027, citing contributions from new product sales and an effective strategic transformation.Key drivers highlighted in the report include the company's 2025 results meeting expectations, with innovative drugs and exclusive products becoming the core growth engine. The skin health business saw remarkable growth of 73.2% year-on-year, supported by plans to spin off Demai Pharmaceutical for a separate listing and the recent approval of a core vitiligo product. A robust product pipeline and significant R&D investments further underpin the positive outlook.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144733107","isCrawlerRequest":true}